Review Article

TNF Tolerance in Monocytes and Macrophages: Characteristics and Molecular Mechanisms

René Huber, Rolf Bikker, Bastian Welz, Martin Christmann, and Korbinian Brand

Institute of Clinical Chemistry, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany

Correspondence should be addressed to René Huber; huber.rene@mh-hannover.de and Korbinian Brand; brand.korbinian@mh-hannover.de

Received 27 July 2017; Accepted 25 September 2017; Published 8 November 2017

Academic Editor: Kebin Hu

Copyright © 2017 René Huber et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Tumor necrosis factor (TNF) tolerance in monocytes and macrophages means that preexposure to TNF reduces the sensitivity in these cells to a subsequent restimulation with this cytokine. Differential effects arise following preincubation with both low and high doses of TNF resulting in absolute as well as induction tolerance affecting specific immunologically relevant gene sets. In this review article, we summarize the relevance of TNF tolerance in vivo and the molecular mechanisms underlying these forms of tolerance including the role of transcription factors and signaling systems. In addition, the characteristics of cross-tolerance between TNF and lipopolysaccharide (LPS) as well as pathophysiological aspects of TNF tolerance are discussed. We conclude that TNF tolerance may represent a protective mechanism involved in the termination of inflammation and preventing excessive or prolonged inflammation. Otherwise, tolerance may also be a trigger of immune paralysis thus contributing to severe inflammatory diseases such as sepsis. An improved understanding of TNF tolerance will presumably facilitate the implementation of diagnostic or therapeutic approaches to more precisely assess and treat inflammation-related diseases.

1. Introduction

TNF is a potent proinflammatory master cytokine modulating inflammatory processes, and its rapid induction is fundamental for the orchestration of the immune response [1]. The application of TNF over a certain time period can result in a reduced sensitivity of cells, organs, or organisms towards a subsequent stimulation with the same cytokine, a phenomenon known as tolerance [2, 3]. TNF tolerance can be induced by a pretreatment of monocytes and macrophages with both low and high doses of TNF and can occur as absolute tolerance or induction tolerance following restimulation [3, 4]. In addition to pure TNF tolerance, several forms of TNF/LPS cross-tolerance have been described [5-7]. In this review, we will summarize the in vivo relevance of TNF tolerance as assessed in different animal models. In addition, we will refer to general features and the known molecular mechanisms underlying different forms of tolerance including the role of transcription factors, signaling systems, and receptors. Finally, the pathophysiological impact of TNF tolerance on both the resolution of inflammation and immune paralysis as well as potential diagnostic and therapeutic aspects targeting tolerance-associated mechanisms or molecules will be discussed.

2. TNF Tolerance In Vivo

TNF tolerance was first described in rats and mice on the basis of reduced physiological responsiveness towards a subsequent stimulation with TNF following a repeated application of sublethal doses of this cytokine within a certain time period [2, 8]. Monocytes and macrophages were early supposed to be important cellular mediators of TNF tolerance [2], and later experiments confirmed that assumption [3, 9] although other cell types (e.g., hepatocytes, cardiomyocytes, or epithelial cells) also proved to be prone to tolerization [10, 11]. In vivo, TNF tolerance is characterized by organo- and cytoprotective effects, as represented by the protection of tolerized mice against subsequent injections of normally lethal TNF doses [12]. Appropriately treated mice, rats, and guinea pigs are protected from inflammation-related symptoms such as fever [13, 14], gastrointestinal toxicity
3. Molecular Characteristics

3.1. General Features of TNF Tolerance. TNF tolerance can be induced by a pretreatment of monocytes and macrophages (or other eligible cells) with both low and high doses of TNF [3, 4, 26]. Typically, low-dose preexposure/incubation was performed using up to 10 μg/kg (mostly human) TNF in animal experiments or up to 20 ng/ml in cell culture experiments [3, 27], while high doses included up to 100 μg/kg in animal studies [2]. It also has to be taken into account that human TNF can induce tolerance in animal experiments using higher doses due to a reduced cytotoxicity, for example, in comparison to murine TNF which proved to be lethal at significantly lower doses [19].

Following restimulation which is always performed using higher TNF concentrations, tolerance can be observed as absolute tolerance or induction tolerance. In absolute tolerance, a low expression of immunologically relevant genes can be found following TNF preincubation which remains on this level even in the case of a subsequent restimulation when compared to the short-term stimulation of naïve cells (Figure 1). Induction tolerance is characterized by an increased expression of genes following long-term preincubation with TNF which is in general roughly comparable with the level observed in naïve cells after short-term stimulation. Following TNF restimulation, the expression of these genes is “frozen” on this level and cannot be further induced (Figure 1). Gene groups affected by absolute and/or induction tolerance are related to cellular functions such as inflammation, growth/differentiation, chemotaxis/migration, signaling/transcription, and metabolism [4]. For instance, genes such as TNF, interleukin (IL-) ββ, IL-6, IL-8, or tissue factor are affected by absolute tolerance, whereas IL-18, IL-28A, IL-32, or toll-like receptor (TLR) 2 are prone to induction tolerance. Although TNF is normally applied for 48–72 h during preincubation [4, 26], a time period of 18 to 24 h has been generally described to be minimally required for the induction of TNF tolerance [5, 12] and enables the maintenance of the tolerated state for several days [12]. However, under certain conditions, even a TNF pretreatment for 2 h appears to be sufficient to induce protection from TNF-dependent cell/organ damage [21]. The signaling network involved in development, consolidation, and regulation of monocytic/macrophagic TNF tolerance is only partially investigated, and only a limited number of cell culture studies characterizing the molecular basis of TNF tolerance exist yet. Currently, it is realized that TNF tolerance is based on a variety of distinct but connected and mutually depending molecular events covering several regulatory spectra of intracellular signal transduction. In the following, the known molecular mechanisms determining TNF tolerance are discussed.

3.2. Low-Dose-Induced Tolerance. Long-term preincubation with low doses of TNF predominantly leads to the
development of absolute tolerance [4]. The expression of most of the genes suppressed under these conditions is regulated by the transcription factors nuclear factor κB (NF-κB) and/or activator protein (AP-) 1 [4, 28] indicating that their limitation is an essential step in restricting the expression of these tolerance-sensitive genes. In low-dose-tolerized and restimulated monocytic cells, IκBα proteolysis, nuclear translocation of p65, and NF-κB DNA binding activity are only weakly affected [26]. However, following restimulation of low-dose-tolerized cells, activation of IL-8 promoter- and κB-dependent transcription is inhibited and p65 phosphorylation at the activating site Ser536 is markedly reduced in murine macrophage-like and monocytic THP-1 cells (["Tohoku Hospital Pediatrics-1", [29]] [4, 9] (Figure 2). The latter effect may be ascribed to an increased association of p65 with the transcription factor CCAAT/enhancer binding protein (C/EBP) β in low-dose-tolerized cells [9]. In this context, protein-protein interaction of p65 and C/EBPβ, which is an important regulator of proliferation and differentiation in myelomonocytic cells [30], results in a blockade of p65-Ser536 (and possibly other activating phosphorylation sites) [9, 31]. In addition, under these conditions (but also in high-dose-tolerized cells), p65 phosphorylation is intensified at Ser468 [4], a phosphorylation site negatively regulating p65 activity [32]. Interestingly, p65-Ser536 phosphorylation is resumed and low-dose TNF-induced tolerance is reversed by glycogen synthesis kinase (GSK) 3 inhibition using SB6763 [4], an effect also described within TNF-induced cross-tolerance towards LPS [6]. Furthermore, it has been reported that GSK3 phosphorylates C/EBPβ [33] as well as p65-Ser468 [32] which suggests a multistep influence of this kinase in TNF tolerance.

Moreover, both low- and high-dose TNF-preincubated THP-1 cells are characterized by attenuated phosphorylation of c-Jun N-terminal kinase (JNK), extracellular signal-regulated kinase (ERK), and p38 [4, 5], that is, kinases targeting (amongst others) AP-1 subunits of the Jun and Fos protein families [34]. Total levels of these kinases, however, appear not to be significantly affected [4, 5]. As a consequence, concentrations of phosphorylated c-Jun were considerably lower in tolerized and restimulated monocytic cells than in stimulated naive cells [4].

In murine models, it has been shown that a blockade of the glucocorticoid receptor (GR) using the antagonist RU-38486 can prevent the occurrence of low-dose-induced TNF tolerance in vivo suggesting that glucocorticoids and their receptor(s) contribute to the formation of tolerance [19]. This might be due to GR-dependent functions such as inhibition of proinflammatory signaling pathways, reduction of AP-1 DNA binding and NF-κB translocation, and induction of anti-inflammatory (e.g., IL-10) as well as down-regulation of proinflammatory cytokine/chemokine (e.g., IL-6, IL-8) expression [35]. For other transcription factors, a role within TNF tolerance has not been established yet. TNF-inducible factors such as activating transcription factor (ATF) or suppressor of cytokine signaling (SOCS-) 1, 2, and 3 have also been discussed with respect to an association with TNF tolerance [21]. However, ATF has not been analysed yet and for SOCS1-3, no influence on tolerance formation could be shown [21].

Taken together, the reported findings indicate that low-dose TNF-induced absolute tolerance is predominantly controlled via transcriptional mechanisms, that is, C/EBPβ-dependent suppression of p65 phosphorylation and potential GSK3 activity (Figure 2). In addition, reduced c-Jun/AP-1 activation and GR-dependent transcriptional repression may contribute to the development of low-dose-induced tolerance.

3.3. High-Dose-Induced Tolerance. Long-term preincubation with high TNF concentrations may result in the development of both absolute and induction tolerance [4]. Following restimulation, nuclear levels of p65 and NF-κB DNA binding activity are significantly reduced in high-dose-tolerized monocytic cells [4] in comparison to naive and low-dose-tolerized cells [26]. In cells, long-term pretreated with high-dose TNF, IκBα turnover is increased and IκBα amounts are reduced to a lower level [4]. Following restimulation,
however, no further stimulus-induced proteolysis of IkBα can be observed. Consistently, it has also been observed that IkB kinase (IKK) phosphorylation is completely inhibited in high-dose pretreated and restimulated cells when compared to naïve cells [4, 36]. In TNF-overexpressing murine cardiomyocytes, additional activation of p50 homodimers has also been found in comparison to control cells and it was speculated that this effect might represent an adaptive response to reduce the detrimental inflammatory consequences of the permanent presence of TNF [11].

Due to the observation that A20 is a key molecule in the establishment of TNF/LPS cross-tolerance [6], its importance within TNF tolerance has also been assessed. A20 is a ubiquitinase/deubiquitinase known for its role as a repressor of NF-κB signaling [37, 38] and characterized by three major functionalities, that is, noncatalytic mechanisms mediating the repression of IKK activation, ubiquitin ligase activity leading to K48-labeling of proteins such as receptor interacting protein (RIP) to induce their proteasomal degradation, and protease activity towards K63 and M1 polyubiquitins [39]. A20 mRNA and protein amounts are markedly upregulated in THP-1 cells as well as primary human monocytes and macrophages pretreated with high TNF doses [4, 36], an effect equivalently occurring in cross-tolerance [6]. The siRNA-dependent knockdown of A20 leads to a strong upregulation of IKK phosphorylation and proinflammatory gene expression in monocytic cells in which TNF tolerance was induced by a high TNF dose [4, 36], indicating that A20 is a major regulator of high-dose-induced tolerance (Figure 3).

A20 interacts and cooperates with additional factors to form the A20 ubiquitin-editing complex, that is, the adaptor molecules Tax1-binding protein 1 (TAX1BP1) and RING-finger protein (RNF) 11 [40, 41] as well as the E3 ubiquitin protein-ligase Itch homolog (Itch) [42] which have been described to support A20 during the regulation of ubiquitin-dependent TNF signaling [43]. Due to their essential contribution to A20 activity, these three proteins appear to be promising candidates in the initiation of TNF tolerance, but neither TAX1BP1 nor RNF11 or Itch was significantly regulated on the mRNA level in monocytic cells incubated with the high TNF dose for 48 h [4, 36]. Beyond initial mRNA expression analyses, however, an involvement of TAX1BP1, RNF11, and Itch in TNF tolerance has not been addressed yet and remains to be established. In contrast, mRNA and protein expression of two other regulators cooperating with A20 is increased in high-dose TNF pretreated monocytic cells [36]; A20 binding inhibitor of NF-κB (ABIN) 1, an A20 adjuvant protein [44], and cylindromatosis susceptibility gene (CYLD), a deubiquitinase possessing activities partly overlapping with A20 [39]. ABIN1 knockdown induced a modest elevation in IL-8 mRNA in TNF long-term-incubated cells which also could not be further elevated by TNF restimulation [36] indicating that ABIN1 cooperates with A20 in mediating TNF tolerance (Figure 3). CYLD knockdown results in an elevation of IL-8 mRNA in TNF long-term preincubated cells which was not further increased when the cells were restimulated with TNF. Effects of A20-siRNA application can be slightly further enhanced using a combination of A20- and CYLD-siRNA [36] suggesting that CYLD contributes to the A20-induced development of TNF tolerance and provides a certain amount of additive effects (Figure 3).

It has also been demonstrated in high-dose-tolerized primary human monocytes that protein phosphorylation is affected by protein phosphatase (PP) 1, an enzyme [45] characterized under these conditions by increased mRNA expression of the catalytic subunit PP1CB and downregulation of the regulatory subunit PP1R14C. Repression of PP1 activity by PP1R14C overexpression or calyculin A treatment resulted in an abolition of high-dose TNF-induced absolute tolerance [4].

Together, these data suggest a model in which high-dose TNF-induced tolerance especially depends on the suppression of NF-κB-associated signaling by A20 which is supported by CYLD and ABIN1 (Figure 3). In addition, phosphatases may also be involved in the formation of TNF tolerance by reducing the global phosphorylation level in TNF preincubated cells.
3.4. Additional Mechanisms. In murine models, TNF tolerance can be induced by human TNF which acts as a selective inducer of murine TNFR1 but not murine TNFR2 [19]. Moreover, tolerance can be induced in TNFR2 knockout mice [16, 21] and the expression of glucocorticoids which may be involved in low-dose-induced TNF tolerance is activated by TNFR1-dependent signaling [19]. Thus, TNF tolerance appears to be mediated via TNFR1 [16, 19]. While total amounts of TNFR1 were not significantly affected during long-term treatment in monocytic THP-1 (high-dose TNF) or SW480 epithelial cells (low-dose TNF) [27, 36], TNF stimulation led to an internalization of the receptor within 2h irrespective of the dose used [36]. Application of low-dose TNF during the preincubation phase, however, resulted in a (slow) recurrence of the initial level of TNFR1 within 48 h. In contrast, the use of high-dose TNF led to a permanent reduction of the receptor on the cell surface during the entire preincubation period, which could be reversed within 24 h when TNF was removed from the medium [36]. This suggests that receptor scarcity at the cell surface is another point restricting TNF-dependent signaling in tolerant cells, at least in primary human monocytes, since TNF pretreatment did not result in the downregulation of TNFR1 at the surface of tolerant murine hepatocytes [16]. However, the major functional role within the establishment of high-dose-induced TNF tolerance appears to be mediated by A20 as discussed above (see Section 3.3).

In mice and primary murine hepatocytes, low-dose TNF preexposure yields decreased amounts of hepatic ubiquitin-specific protease (USP) 2 [10]. Downregulation of USP2, either induced by TNF treatment or artificially using siRNA, resulted in the prevention of TNF-induced apoptosis, an effect occurring in combination with increased levels of cellular FLICE-like inhibitory protein (cFLIP), an antiapoptotic molecule [46], and downregulation of Itch [10], which acts as a cFLIP inhibitor in that context [47]. Vice versa, USP2 overexpression inhibited the establishment of TNF tolerance [10] indicating that USP2 represents a powerful inhibitor of tolerization, at least in the murine hepatic system.

4. Cross-Tolerance

The TNF-tolerant state may further include the refractoriness towards other stimuli. For instance, cells or animals tol- erized with TNF are cross-tolerant towards gram-negative bacteria [7, 18], LPS [2, 6, 27], or other bacteria-derived agents such as lipophilic outer membrane vesicles [7]. Vice versa pretreatment with LPS [5, 48] or macrophage-activating lipopeptide 2 [49] induced the development of tolerance towards subsequent TNF application in THP-1 cells or mice and rats. Interestingly, tolerance may also be a result of certain infections, since adenoviral infection of mice has been described to yield a tolerance-like condition towards TNF treatment [24].

Due to the equivalent conditions they are creating especially in monocytes and macrophages, TNF tolerance and cross-tolerance appear to be based in part on overlapping or at least similarly operating molecular mechanisms. This assumption is already well substantiated in the literature revealing that both TNF- and LPS-induced tolerance/crosstolerance are characterized by (1) decreased NF-κB activity in the nucleus under certain conditions [4, 50], (2) GR-dependent gene regulation [19, 51], (3) attenuated mitogen-activated protein kinase phosphorylation [4, 5], (4) regulatory influence of GSK3 activity [4, 6], (5) upregulation of A20 [6, 36], and (6) receptor downregulation at the cell surface [36, 51]. Together, these events finally lead to an inhibition of (primarily NF-κB-dependent) proinflammatory gene expression and the manifestation of a widely inert cellular state. However, since TNF tolerance and LPS/TNF cross-tolerance are established via different receptors (TNFR1 versus TLR4) [19, 50] and TNF tolerance is induced less rapidly by TNF than by LPS [22], specific mechanisms (depending on the respective inducer) influencing the unique features of both phenomena also have to exist.

Moreover, it has been described that the application of further agents can positively or negatively modulate the occurrence of TNF tolerance. For instance, the combined treatment of mice with TNF and leukemia inhibitory factor results in a significantly increased protective effect against a (generally lethal) LPS dose when compared to TNF application alone [52]. In contrast, the addition of human IL-1 completely prevented the development of TNF tolerance in mice normally induced by human TNF [19]. This indicates that an interaction or cross-reaction with other signaling pathways and regulatory events may modulate the events determining the occurrence of tolerance.

5. Pathophysiological Aspects of TNF Tolerance

To prevent deleterious consequences of inflammatory events such as excessive or chronic inflammation, a strictly controlled and fine-tuned termination of inflammatory processes is required [53-55]. As illustrated in this review, different forms of TNF tolerance can be observed following long-term (>24 h) preexposure to TNF [4, 5, 26]. The signal- ing quality occurring during the development of TNF tol- erance significantly differs from the massive temporary activation of TNF-dependent signaling within the first 12 h of stimulation which has been characterized extensively [1, 56] and designated as phases I and II of TNF signaling [57]. Thus, TNF tolerance may play a role as a mechanism mediating refractoriness of monocytes and macrophages towards sustained proinflammatory cell activation in phase III (>12 h) of cytokine stimulation [36].

Due to its immunomodulatory effects, TNF tolerance may comprise several clinical implications in inflammatory and malignant diseases and represents a “Jekyll and Hyde”-like cellular process. On the one hand, tolerance may be a beneficial mechanism contributing to the resolution of inflammation and the protection from sepsis-associated hyperinflammation or prolonged chronic inflammatory dis- eases. In this context, loss of tolerance may favour the formation of chronic TNF-dependent inflammatory diseases in which NF-κB is activated such as rheumatoid arthritis [58], inflammatory bowel disease [59], or autoimmunity [60]. On the other hand, “too much tolerance” may be regarded as a deleterious event presumably involved in the development
of immune paralysis and the shutdown of the immune system observed during certain phases of sepsis [61-63] (Figure 4). The balance between protection against excessive inflammation and immune paralysis may finally determine a patient’s fate [62]. In malignant diseases, refractoriness towards TNF may also play a role [64]. For instance, it has been observed that tumour formation may occur as an adverse event of anti-TNF treatment in several inflammatory diseases [1].

6. Conclusions

As summarized in this review, TNF tolerance is generally characterized by the inability of affected cells, organs, or organisms to fully respond to a restimulation with TNF following a preceding long-term incubation with the same stimulus. Thus, TNF tolerance may play a role in severe acute or chronic inflammatory diseases in which TNF is present in large amounts. As such, TNF tolerance appears to be an interesting target within the efforts to improve the therapeutic modulation of exaggerated and/or prolonged dysregulated immune responses. However, despite a variety of experimental approaches and considerable progress in the characterization of its molecular regulation in recent years, the complex network of mechanisms determining occurrence and establishment of TNF tolerance is not completely elucidated yet. In addition, the distinct role of TNF tolerance in development and progression of inflammation-related diseases as well as its clinical relevance has to be precisely established [65].

A better characterization of the mechanisms determining TNF tolerance will improve the understanding of its clinical relevance and presumably facilitate the development of diagnostic approaches to assess different forms and states of tolerance. In addition, increased knowledge on TNF tolerance potentially offers the implementation of therapeutic approaches to treat inflammation-related diseases either by initiating or breaking the establishment of TNF tolerance.

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| ABIN:        | A20 binding inhibitor of NF-κB |
| AP-1:        | Activator protein 1 |
| ATF:         | Activating transcription factor |
| C/EBP:       | CCAAT/enhancer binding protein |
| cFLIP:       | Cellular FLICE-like inhibitory protein |
| CYLD:        | Cylindromatosis susceptibility gene |
| ERK:         | Extracellular signal-regulated kinase |
| GSK:         | Glycogen synthase kinase |
| GR:          | Glucocorticoid receptor |
| IkB:         | Inhibitor of (NF-)κB |
| IKK:         | IkB kinase |
| IL:          | Interleukin |
| Itch:        | E3 ubiquitin protein-ligase Itchy homolog |
| JNK:         | Jun N-terminal kinase |
| LPS:         | Lipopolysaccharide |
| NF-κB:       | Nuclear factor κB |
| PP:          | Protein phosphatase |
| RIP:         | Receptor interacting protein |
| RNF11:       | RING-finger protein 11 |
| SOCS:        | Suppressor of cytokine signaling |
| TAX1BP1:     | Tax1-binding protein 1 |
| THP-1:       | Tohoku Hospital Pediatrics-1 |
| TLR:         | Toll-like receptor |
| TNF:         | Tumor necrosis factor |
| TNFR:        | Tumor necrosis factor receptor |
| USP:         | Ubiquitin-specific protease |

Conflicts of Interest

The authors declare that they have no conflict of interests.

Acknowledgments

The authors are very thankful to Professor Dr. H.W. Löms Zieger-Heitbrock, Professor Dr. Kyeong-Hee Lee, Dr. Nico Föger, Dr. Konstantin Neumann, and Mrs. Katharina Preuß for numerous critical discussions. The authors thank Mrs. Cornélia La Fougère-Brand for critical reading of the manuscript and apologize to all authors/working groups whose work has not been considered for this review due to space limitations or oversight. This work was supported by the German Research Foundation (Grant SFB 566/B17) and the Stiftung für Pathobiochemie und Molekulare Diagnostik der Deutschen Gesellschaft für Klinische Chemie und Laboratoriumsmedizin (DGKL).

References

[1] D. Brenner, H. Blaser, and T. W. Mak, “Regulation of tumour necrosis factor signalling: live or let die,” Nature Reviews Immunology, vol. 15, no. 6, pp. 362–374, 2015.

[2] D. L. Fraker, M. C. Stovroff, M. J. Merino, and J. A. Norton, “Tolerance to tumor necrosis factor in rats and the
relationship to endotoxin tolerance and toxicity," The Journal of Experimental Medicine, vol. 168, no. 1, pp. 95–105, 1988.

[3] B. Zingarelli, M. Makhoulf, P. Halushka, A. Caputi, and J. A. Cook, "Altered macrophage function in tumor necrosis factor α- and endotoxin-induced tolerance," Journal of Endotoxin Research, vol. 2, pp. 247–254, 1995.

[4] J. Gunther, N. Vogt, K. Hampel et al., "Identification of two forms of TNF tolerance in human monocytes: differential inhibition of NF-κB/AP-1 and PP1-associated signaling," The Journal of Immunology, vol. 192, no. 7, pp. 3143–3155, 2014.

[5] M. Ferlito, O. G. Romanenko, S. Ashton, F. Squadrito, P. V. Halushka, and J. A. Cook, "Effect of cross-tolerance between endotoxin and TNF-α or IL-1β on cellular signaling and mediator production," Journal of Leukocyte Biology, vol. 70, no. 5, pp. 821–829, 2001.

[6] S. H. Park, K. H. Park-Min, J. Chen, X. Hu, and L. B. Ivashkiv, "Tumor necrosis factor induces GSK3 kinase–mediated cross-tolerance to endotoxin in macrophages," Nature Immunology, vol. 12, no. 7, pp. 607–615, 2011.

[7] T. Waller, L. Kesper, J. Hirschfeld et al., "Porphyromonas gingivalis outer membrane vesicles induce selective tumor necrosis factor tolerance in a toll-like receptor 4- and mTOR-dependent manner," Infection and Immunity, vol. 84, no. 4, pp. 1194–1204, 2016.

[8] D. L. Fraker, C. B. Sheppard, and J. A. Norton, "Impact of tolerance on antitumor efficacy of tumor necrosis factor in mice," Cancer Research, vol. 50, no. 8, pp. 2261–2267, 1990.

[9] A. Zwergal, M. Quiring, B. Sauge et al., "C/EBPβ blocks p65 phosphorylation and thereby NF-κB-mediated transcription in TNF-tolerant cells," The Journal of Immunology, vol. 177, no. 1, pp. 665–672, 2006.

[10] F. Haimerl, A. Erhardt, G. Sass, and G. Tieg, "Down-regulation of the de-ubiquitinating enzyme ubiquitin-specific protease 2 contributes to tumor necrosis factor-α-induced hepatocyte survival," The Journal of Biological Chemistry, vol. 284, no. 1, pp. 495–504, 2009.

[11] S. B. Haudek, D. D. Bryant, and B. P. Giroir, "Differential regulation of myocardial NF-κB following acute or chronic TNF-α exposure," Journal of Molecular and Cellular Cardiology, vol. 33, no. 6, pp. 1263–1271, 2001.

[12] B. C. Sheppard and J. A. Norton, "Tumor necrosis factor and interleukin-1 protection against the lethal effects of tumor necrosis factor," Surgery, vol. 109, no. 6, pp. 698–705, 1991.

[13] J. J. Klor, J. L. McClellan, W. Kozak, Z. Szlenyi, G. H. Wong, and M. J. Kluger, "Systemic but not central administration of tumor necrosis factor-α attenuates LPS-induced fever in rats," American Journal of Physiology, vol. 268, no. 2, pp. R480–R486, 1995.

[14] J. M. Goldbach, J. Roth, B. Storr, and E. Zeisberger, "Repeated infusions of TNF-α cause attenuation of the thermal response and influence LPS fever in guinea pigs," American Journal of Physiology, vol. 270, no. 4, pp. R749–R754, 1996.

[15] J. S. Patton, P. M. Peters, J. McCabe et al., "Development of partial tolerance to the gastrointestinal effects of high doses of recombinant tumor necrosis factor-alpha in rodents," The Journal of Clinical Investigation, vol. 80, no. 6, pp. 1587–1596, 1987.

[16] G. Sass, K. Koerber, and G. Tieg, "TNF tolerance and cytotoxicity in the liver: the role of interleukin-1β, inducible nitric oxide-synthase and heme oxygenase-1 in D-galactosamine-sensitized mice," Inflammation Research, vol. 51, no. 5, pp. 229–235, 2002.

[17] S. H. Socher, A. Friedman, and D. Martinez, "Recombinant human tumor necrosis factor induces acute reductions in food intake and body weight in mice," The Journal of Experimental Medicine, vol. 167, no. 6, pp. 1957–1962, 1988.

[18] H. R. Alexander, B. C. Sheppard, J. C. Jensen et al., "Treatment with recombinant human tumor necrosis factor-alpha protects rats against the lethality, hypotension, and hyperthermia of gram-negative sepsis," The Journal of Clinical Investigation, vol. 88, no. 1, pp. 34–39, 1991.

[19] N. Takahashi, P. Brouckaert, and W. Fiers, "Mechanism of tolerance to tumor necrosis factor: receptor-specific pathway and selectivity," American Journal of Physiology, vol. 269, no. 2, pp. R398–R405, 1995.

[20] R. S. Hotchkiss and D. W. Nicholson, "Apoptosis and caspases regulate death and inflammation in sepsis," Nature Reviews Immunology, vol. 6, no. 11, pp. 813–822, 2006.

[21] G. Sass, N. D. Shembade, and G. Tieg, "Tumour necrosis factor α (TNF–) TNF receptor 1-inducible cytoprotective proteins in the mouse liver: relevance of suppressors of cytokine signaling," Biochemical Journal, vol. 385, no. 2, pp. 537–544, 2005.

[22] M. H. Porter, M. Arnold, and W. Langhans, "TNF-α tolerance blocks LPS-induced hypoglycaemia but LPS tolerance fails to prevent TNF-α-induced hypoglycaemia," American Journal of Physiology, vol. 274, no. 3, pp. R741–R745, 1998.

[23] D. B. Hill, J. Schmidt, S. I. Shedlofsky, D. A. Cohen, and C. J. McClain, "In vitro tumor necrosis factor cytotoxicity in Hep G2 liver cells," Hepatology, vol. 21, no. 4, pp. 1114–1119, 1995.

[24] T. O. Yarovinsky, L. S. Powers, N. S. Butler, M. A. Bradford, M. M. Monick, and G. W. Hunninghake, "Adenoviral infection decreases mortality from lipopolysaccharide-induced liver failure via induction of TNF-α tolerance," The Journal of Immunology, vol. 171, no. 5, pp. 2453–2460, 2003.

[25] I. A. Clark, G. Chaudhuri, and W. B. Cowden, "Roles of tumour necrosis factor in the illness and pathology of malaria," Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 83, no. 4, pp. 436–440, 1989.

[26] M. Weber, C. Sydilk, M. Quiring et al., "Transcriptional inhibition of interleukin-8 expression in tumor necrosis factor-tolerant cells: evidence for involvement of C/EBPβ," The Journal of Biological Chemistry, vol. 278, no. 26, pp. 23586–23593, 2003.

[27] A. Laegreid, L. Thommesen, T. G. Jähr, A. Sundan, and T. Espevik, "Tumor necrosis factor induces lipopolysaccharide tolerance in a human adenocarcinoma cell line mainly through the TNF p55 receptor," The Journal of Biological Chemistry, vol. 270, no. 43, pp. 25418–25425, 1995.

[28] I. Ginis, R. Jaiswal, D. Klimanis, J. Liu, J. Greenspon, and J. M. Hallenbeck, "TNF-α-induced tolerance to ischemic injury involves differential control of NF-κB transactivation: the role of NF-κB association with p300 adaptor," Journal of Cerebral Blood Flow & Metabolism, vol. 22, no. 2, pp. 142–152, 2002.

[29] S. Tsuchiya, M. Yamabe, Y. Yamaguchi, Y. Kobayashi, T. Konno, and K. Tada, "Establishment and characterization of a human acute monocytic leukemia cell line (THP-1)," International Journal of Cancer, vol. 26, no. 2, pp. 171–176, 1980.

[30] R. Huber, D. Pietsch, J. Gunther, B. Welz, N. Vogt, and K. Brand, "Regulation of monocyte differentiation by specific
signaling modules and associated transcription factor networks," *Cellular and Molecular Life Sciences*, vol. 71, no. 1, pp. 63–92, 2014.

[31] R. Huber, D. Pietsch, T. Panerodt, and K. Brand, "Regulation of C/EBPβ and resulting functions in cells of the monocytic lineage," *Cellular Signalling*, vol. 24, no. 6, pp. 1287–1296, 2012.

[32] H. Buss, A. Dörrie, M. L. Schmitz et al., "Phosphorylation of serine 468 by GSK-3β negatively regulates basal p65 NF-κB activity," *The Journal of Biological Chemistry*, vol. 279, no. 48, pp. 49571–49574, 2004.

[33] F. Shen, N. Li, P. Gade et al., "IL-17 receptor signaling inhibits C/EBPβ by sequential phosphorylation of the regulatory 2 domain," *Science Signaling*, vol. 2, no. 59, article ra8, 2009.

[34] G. Sabio and R. J. Davis, "TNF and MAP kinase signalling pathways," *Seminars in Immunology*, vol. 26, no. 3, pp. 237–245, 2014.

[35] K. A. Zielinska, L. Van Moortel, G. Opdenakker, K. De Bosscher, and P. E. Van den Steen, "Endothelial response to glucocorticoids in inflammatory diseases," *Frontiers in Immunology*, vol. 7, p. 592, 2016.

[36] R. Bikker, M. Christmann, K. Preuß et al., "TNF phase III signalling in tolerant cells is tightly controlled by A20 and CYLD," *Cellular Signalling*, vol. 37, pp. 123–135, 2017.

[37] I. E. Wertz, K. M. O’Rourke, H. Zhou et al., "De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling," *Nature*, vol. 430, no. 7000, pp. 694–699, 2004.

[38] I. E. Wertz, K. Newton, D. Seshasayee et al., "Phosphorylation and linear ubiquitin direct A20 inhibition of inflammation," *Nature*, vol. 528, no. 7582, pp. 370–375, 2015.

[39] M. Lork, K. Verhelst, and R. Beyaert, "CYLD, A20 and OTU-LIN deubiquitinas in NF-κB signaling and cell death: so similar, yet so different," *Cell Death and Differentiation*, vol. 24, no. 7, pp. 1172–1183, 2017.

[40] N. Shembade, R. Pujari, N. S. Harhaj, D. W. Abbott, and E. W. Harhaj, "The kinase IKKα inhibits activation of the transcription factor NF-κB by phosphorylating the regulatory molecule TAX1BP1," *Nature Immunology*, vol. 12, no. 9, pp. 834–843, 2011.

[41] N. Shembade, K. Parvatiyar, N. S. Harhaj, and E. W. Harhaj, "The ubiquitin-editing enzyme A20 requires RNF11 to down-regulate NF-κB signalling," *The EMBO Journal*, vol. 28, no. 5, pp. 513–522, 2009.

[42] N. Shembade, N. S. Harhaj, K. Parvatiyar et al., "The E3 ligase Itch negatively regulates inflammatory signalling pathways by controlling the function of the ubiquitin-editing enzyme A20," *Nature Immunology*, vol. 9, no. 3, pp. 254–262, 2008.

[43] A. Ma and B. A. Malynn, "A20: linking a complex regulator of ubiquitination to immunity and human disease," *Nature Reviews Immunology*, vol. 12, no. 11, pp. 774–785, 2012.

[44] L. Verstrepen, I. Carpentier, K. Verhelst, and R. Beyaert, "ABINs: A20 binding inhibitors of NF-κB and apoptosis signaling," *Biochemical Pharmacology*, vol. 78, no. 2, pp. 105–114, 2009.

[45] I. Verbrinnen, M. Ferreira, and M. Bollen, "Biogenesis and activity regulation of protein phosphatase 1," *Biochemical Society Transactions*, vol. 45, no. 1, pp. 89–99, 2017.

[46] Y. Tsuchiya, O. Nakabayashi, and H. Nakano, "FLIP: the switch: regulation of apoptosis and necroptosis by cFLIP," *International Journal of Molecular Sciences*, vol. 16, no. 12, pp. 30321–30341, 2015.

[47] D. Aki, W. Zhang, and Y. C. Liu, "The E3 ligase Itch in immune regulation and beyond," *Immunological Reviews*, vol. 266, no. 1, pp. 6–26, 2015.

[48] M. Goto, T. Yoshioka, R. I. Young, T. Battelino, C. L. Anderson, and W. P. Zeller, "A sublethal dose of LPS to pregnant rats induces TNF-alpha tolerance in their 0-day-old offspring," *American Journal of Physiology*, vol. 273, no. 3, pp. R1158–R1162, 1997.

[49] U. Deiters, M. Gumscheimer, C. Galanos, and P. F. Muhrladt, "Toll-like receptor 2- and 6-mediated stimulation by macrophage-activating lipopeptide 2 induces lipopolysaccharide (LPS) cross tolerance in mice, which results in protection from tumor necrosis factor alpha but in only partial protection from lethal LPS doses," *Infection and Immunity*, vol. 71, no. 8, pp. 4456–4462, 2003.

[50] J. J. Seeley and S. Ghosh, "Tollerization of inflammatory gene expression," *Cold Spring Harbor Symposia on Quantitative Biology*, vol. 78, pp. 69–79, 2013.

[51] H. W. Ziegler-Heitbrock, "Molecular mechanism in tolerance to lipopolysaccharide," *Journal of Inflammation*, vol. 45, no. 1, pp. 13–26, 1995.

[52] H. R. Alexander, G. G. Wong, G. M. Doherty, D. J. Venzon, D. L. Fraker, and J. A. Norton, "Differentiation factor/leukemia inhibitory factor protection against lethal endotoxemia in mice: synergistic effect with interleukin 1 and tumor necrosis factor," *The Journal of Experimental Medicine*, vol. 175, no. 4, pp. 1139–1142, 1992.

[53] C. D. Buckley, D. W. Gilroy, C. N. Serhan, B. Stockinger, and P. P. Tak, "The resolution of inflammation," *Nature Reviews Immunology*, vol. 13, no. 1, pp. 59–66, 2013.

[54] C. Nathan and A. Ding, "Nonresolving inflammation," *Cell*, vol. 140, no. 6, pp. 871–882, 2010.

[55] C. N. Serhan and J. Savill, "Resolution of inflammation: the beginning programs the end," *Nature Immunology*, vol. 6, no. 12, pp. 1191–1197, 2005.

[56] L. M. Workman and H. Habelhah, "TNFR1 signaling kinetics: spatiotemporal control of three phases of IKK activation by posttranslational modification," *Cellular Signalling*, vol. 25, no. 8, pp. 1654–1664, 2013.

[57] S. L. Werner, J. D. Kearns, V. Zadorozhnaya et al., "Encoding NF-κB temporal control in response to TNF: distinct roles for the negative regulators IκBα and A20," *Genes & Development*, vol. 22, no. 15, pp. 2093–2101, 2008.

[58] G. S. Firestein and I. B. McInnes, "Immunopathogenesis of rheumatoid arthritis," *Immunity*, vol. 46, no. 2, pp. 183–196, 2017.

[59] G. Rogler, K. Brand, D. Vogl et al., "Nuclear factor xB is activated in macrophages and epithelial cells of inflamed intestinal mucosa," *Gastroenterology*, vol. 115, no. 2, pp. 357–369, 1998.

[60] J. J. O'Shea, A. Ma, and P. Lipsky, "Cytokines and autoimmunity," *Nature Reviews Immunology*, vol. 2, no. 1, pp. 37–45, 2002.

[61] R. S. Hotchkiss and I. E. Karl, "The pathophysiology and treatment of sepsis," *The New England Journal of Medicine*, vol. 348, no. 2, pp. 138–150, 2003.

[62] R. S. Hotchkiss, G. Monneret, and D. Payen, "Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy," *Nature Reviews Immunology*, vol. 13, no. 12, pp. 862–874, 2013.
[63] R. S. Hotchkiss, L. L. Moldawer, S. M. Opal, K. Reinhart, I. R. Turnbull, and J. L. Vincent, "Sepsis and septic shock," *Nature Reviews Disease Primers*, vol. 2, article 16045, 2016.

[64] F. Balkwill, “Tumour necrosis factor and cancer,” *Nature Reviews Cancer*, vol. 9, no. 5, pp. 361–371, 2009.

[65] J. N. Fullerton and D. W. Gilroy, “Resolution of inflammation: a new therapeutic frontier,” *Nature Reviews Drug Discovery*, vol. 15, no. 8, pp. 551–567, 2016.